James Waldron reported on how GRObio’s $60.3 million Series B financing allows the Company to acquire clinical efficacy for its lead program in chronic refractory gout, and how our approach improves upon the current standard of care.
From the article: “Gout occurs when high levels of uric acid in the blood cause crystals to form and accumulate in and around a joint, leading to pain and swelling. Horizon Therapeutics’ Krystexxa remains the only approved biologic to treat uncontrolled gout. But some patients who receive this uricase enzyme therapy soon develop anti-drug antibodies (ADAs) that clear out the enzyme, according to GRO Bio.”
